Global Aneurysmal Subarachnoid Hemorrhage Market - Industry Trends and Forecast to 2028

Market Analysis and Insights: Global Aneurysmal Subarachnoid Hemorrhage Market

Global Aneurysmal Subarachnoid Hemorrhage market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.40% in the above-mentioned research forecast period.

The aneurysmal subarachnoid hemorrhage (SAH) is a global health burden with increased cases of high mortality rates and permanent disability rates. The total projection depends on the capacity of the initial bleed, repeated bleeding and grade of late cerebral ischemia. The severity of SAH is neurogenic pulmonary edema and cardiac manipulations. It is caused by a ruptured aneurysm or head injury. The global incidence of aneurysmal subarachnoid hemorrhage (SAH) across all surveys was 7.9 per 100,000 person years. The aneurysms in the brain are quite frequent in women, smokers and the individuals suffering from high blood pressure. A slight trauma or injury to the brain can cause aneurysm and results in subarachnoid hemorrhage. To diagnose SAH, a CT scan of the brain should be performed. If the results found are invalid, the medical practitioner can use a contrast dye during the procedure. The other tests which can be used to detect the presence of hemorrhage are cerebral angiography; which utilizes an X-Ray, and the injected dye to detect flow of blood within the arteries. To check blood flow within the brain can be detected by transcranial ultrasound. The lumbar puncture is used to check if the blood cells are found in the cerebrospinal fluid (CSF). Certain risk factors have been under notice for SAH. The data collected by Internet Stroke Centre states that women are most probably going to develop brain aneurysms than men. Medications provided to treat SAH are Nimodipine, anticonvulsants (phenytoin), antiemetics (promethazine).

The increased count of hemorrhage clots and hypertension rising focus on minimally invasive surgery, growth in geriatric population, increasing number of lifestyle disorders (smoking, alcohol consumption) rise in disposable income among the consumers are predicted to drive the market growth. However, the rise in cost and lack of awareness among population about the symptoms and prevention of aneurysmal subarachnoid hemorrhage (SAH), the risk factors associated and unfavorable reimbursement framework are expected to hinder the market growth. The rise of emerging markets and upcoming healthcare, clinics and diagnostic centres and strategic ingenuities by major players and recent innovations would provide lucrative opportunities which are projected to bolster the market growth. The use of alternatives, lack of skilled expertise increase in product manufacturing costs and rise in product recalls are the challenges which can tamper the market growth.

This Aneurysmal Subarachnoid Hemorrhage market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Aneurysmal Subarachnoid Hemorrhage Market Scope and Market Size

The aneurysmal subarachnoid hemorrhage market is segmented on the basis of drug class, treatment type, route of administration, mode of purchase, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of drug class, the aneurysmal subarachnoid hemorrhage market is segmented into antiemetics, anticonvulsants, nimodpine.
• On the basis of treatment type, the aneurysmal subarachnoid hemorrhage market is segmented into CT scan, MRI scan, and cerebral angiography, transcranial ultrasound, lumbar puncture.
• On the basis of route of administration, the aneurysmal subarachnoid hemorrhage market is segmented into intravenous, oral, parenteral.
• On the basis of mode of purchase, the aneurysmal subarachnoid hemorrhage market is segmented into prescription and over the counter.
• On the basis of distribution channel, the aneurysmal subarachnoid hemorrhage market has also been segmented into hospital pharmacies, retail pharmacies, online pharmacies.

Aneurysmal Subarachnoid Hemorrhage Market Country Level Analysis

Aneurysmal subarachnoid hemorrhage market is analysed and market size information is provided by country, drug class, treatment type, route of administration, mode of purchase, and distribution channel as referenced above.

The countries covered in the aneurysmal subarachnoid hemorrhage market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America is expected to hold the largest market share due to the increase in geriatric population, availability of healthcare amenities and rising presence of drug approvals. Nimodipine is the only FDA- approved agent for cerebral vasospasm and Aneurysmal Subarachnoid Hemorrhage Asia Pacific is expected to become the fastest growing market due to rise in untapped opportunities in developing countries, increased investments by market players and rise in research and development activities

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Aneurysmal subarachnoid hemorrhage market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Aneurysmal Subarachnoid Hemorrhage Market Share Analysis

Aneurysmal Subarachnoid Hemorrhagemarket competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Aneurysmal Subarachnoid Hemorrhagemarket.

The major players covered in the aneurysmal subarachnoid hemorrhage market are EDGE Therapeutics, Inc, Mylan, arbor PHARMACEUTICALS, LLC, PURDUE, Johnson & Johnson Services, Inc (ACTELION), Orexo AB, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Pharmaxis Ltd, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-60402